000			01915 a2200541 4500
005			20250515225212.0
264		0	_c20101116
008			201011s 0 0 eng d
022			_a1029-2403
024	7		_a10.3109/10428194.2010.490312 _2doi
040			_aNLM _beng _cNLM
100	1		_aLim, Wah-Seng
245	0	0	_aSchedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. _h[electronic resource]
260			_bLeukemia & lymphoma _cAug 2010
300			_a1536-42 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacokinetics
650	0	4	_aBone Marrow Cells _xdrug effects
650	0	4	_aChemistry, Pharmaceutical
650	0	4	_aCytarabine _xadministration & dosage
650	0	4	_aDNA-Binding Proteins _xphysiology
650	0	4	_aDaunorubicin _xadministration & dosage
650	0	4	_aDosage Forms
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Synergism
650	0	4	_aFemale
650	0	4	_aFlow Cytometry
650	0	4	_aHumans
650	0	4	_aLiposomes
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMice
650	0	4	_aPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy
650	0	4	_aSurvival Rate
650	0	4	_aTissue Distribution
650	0	4	_aTumor Cells, Cultured
650	0	4	_aXenograft Model Antitumor Assays
700	1		_aTardi, Paul G
700	1		_aXie, Xiaowei
700	1		_aFan, Mannie
700	1		_aHuang, Ruby
700	1		_aCiofani, Travis
700	1		_aHarasym, Troy O
700	1		_aMayer, Lawrence D
773	0		_tLeukemia & lymphoma _gvol. 51 _gno. 8 _gp. 1536-42
856	4	0	_uhttps://doi.org/10.3109/10428194.2010.490312 _zAvailable from publisher's website
999			_c19878670 _d19878670